Thomas Niel

Thomas Niel

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

With Greenridge Stock Bottoming, It May Be Time to Buy Some Shares

With GREE stock stabilizing after its post-merger selloff, it may be worth initiating a bullish position in this crypto mining play.

7 Penny Stocks to Pick Up if You Have $100 to Spare

They're not exactly names you want to bet the ranch on. Still, a $100 position in each of these penny stocks could be worth the risk.

Production Progress May Enable Lucid Stock to Hold Steady

The early-stage EV company's recent developments may enable LCID stock to perform relatively well in the volatile market.

Don’t Be Surprised if This Latest Shiba Inu Rally Runs out of Gas

Yes, there's a chance you can chase Shiba Inu now, and see it double once again. If that happens? Consider it good luck, and not the product of good prognostication.

Even in a Volatile Market, You’ll Want to Buy SoFi Stock

SOFI stock could trade sideways (or lower) in the months ahead, but now may be time to enter a long-term position.

7 Most-Hated Stocks on Wall Street That Are Actually Hidden Gems

Which out-of-favor, most-hated stocks look like great buys right now? These knocked-down names may have a chance to climb again.

SAVA Stock Is a Buy Here Despite the Very Real Risks It Faces

Like with any biotech situation, where it's big possible gains against large possible losses, caution is key. But for investors who approach SAVA stock accordingly, and are able to ride out any future near-term dips in price? It may be a gamble worth taking.

Despite Game-Changing Treatment News, It’s Not Over for Novavax Yet

Merck's Covid-19 treatment pill may have changed the story for NVAX stock. However, if it tumbles further, the stock could become a buy again.

Wait for Weakness Before Buying Carnival Stock

With Carnival's "recovery" fully priced into CCL stock, it isn't sailing back to $50 per share. So steer clear of it for now.

Algorand Is Still at the Ground Floor, But Tread Carefully

Risk/return remains in your favor with Algorand. But also be careful, as market volatility could send it lower in the short term.